Melanotan-1 Dosage Chart & FDA Protocol (2026) | The Peptide Catalog
Melanotan-1 dosing guide with FDA-approved data, injection protocols, loading/maintenance schedule, and side effects.
Melanotan-1 Dosage Chart & FDA Protocol (2026) | The Peptide Catalog
Melanotan-1 dosing guide with FDA-approved data, injection protocols, loading/maintenance schedule, and side effects.
Melanotan-1 (afamelanotide) is a synthetic analog of alpha-melanocyte stimulating hormone (α-MSH) that stimulates melanin production for photoprotection. Unlike its cousin Melanotan-2, it’s FDA-approved and has a much cleaner side effect profile.
FDA Status: Approved for erythropoietic protoporphyria (EPP). Community protocols extrapolate from this clinical data. This is not medical advice.
Quick Reference: Community Dosing
If you’re here for the practical protocol, here it is:
Most people start with 250 mcg twice weekly (Monday/Thursday) combined with gradual UV exposure. Loading takes 2–4 weeks to build base tan. For detailed reconstitution math, see the Reconstitution Guide below.
For the full Melanotan-1 peptide profile, vendor pricing, and comparison with MT-2, see our Melanotan-1 peptide page.
Loading vs Maintenance
A two-phase approach mirrors the natural tanning process:
Loading (Weeks 1–4): 250 mcg twice weekly with daily UV exposure (15–30 minutes, gradually increasing). This builds baseline melanin production and photoprotective capacity.
Maintenance (Weeks 5–8): Continue 250 mcg twice weekly or drop to once weekly, with regular but less intensive UV exposure to maintain tan.
This protocol mimics the natural seasonal pattern — building protection in spring, maintaining through summer ( Langendonk et al., 2015).
Typical Protocol Lengths
- Seasonal tanning: 8–12 weeks before summer
- Vacation prep: 4–6 weeks before tropical trips
- Year-round maintenance: 8 weeks on, 8 weeks off (cycling)
- EPP photoprotection: Continuous as prescribed (clinical use only)
Routes of Administration
Subcutaneous Injection (Standard Route)
The primary route for community protocols. Inject into abdominal subcutaneous tissue.
- Injection site — Abdomen or love handle area. Rotate sites to prevent tissue irritation.
- Needle — 29–31 gauge insulin syringe for comfort and accuracy
- Volume — Typically 0.05–0.1 mL per injection
Timing: Morning injections are preferred as they align with natural circadian melanocortin rhythms.
Subcutaneous Implant (Clinical Only)
The FDA-approved route uses a 16mg biodegradable implant placed subcutaneously every 60 days. This is only available through specialized clinical programs for EPP patients and provides continuous release over 2 months ( Langendonk et al., 2015).
Not Recommended Routes
Unlike some peptides, Melanotan-1 is not effective:
- Oral — Degraded by stomach acid and poor bioavailability
- Nasal — No established protocols or safety data
- Topical — Molecule too large for skin penetration
Where These Numbers Come From: Clinical Context
Community dosing isn’t guesswork — it’s extrapolated from FDA-approved clinical data and early clinical trials.
FDA-Approved Dosing
Afamelanotide is FDA-approved for EPP at 16mg subcutaneous implant every 60 days. This provides roughly 2mg per day of continuous release over 8 weeks ( Langendonk et al., 2015).
Early Clinical Trial Data
Phase II trials in healthy volunteers used various injection protocols:
- 0.16 mg/kg subcutaneous injections (Barnetson et al., 2006)
- 0.25 mg daily subcutaneous for photoprotection studies
- 1 mg every other day in some tanning studies
Bridge to Community Protocols
The community’s 250 mcg twice weekly (0.5 mg/week) is conservative compared to clinical data:
Why Community Doses Are Lower:
- Community users want tanning, not maximum photoprotection for rare disease
- Lower doses reduce side effects while maintaining efficacy
- Intermittent dosing prevents receptor desensitization
- Combined with UV exposure, lower doses are effective for melanogenesis
Reconstitution Guide
Melanotan-1 comes as lyophilized powder. Reconstitute with bacteriostatic water before use.
What You Need
- Melanotan-1 vial (10 mg typical)
- Bacteriostatic water (BAC water) — 0.9% benzyl alcohol preservative
- Insulin syringes (29–31 gauge)
- Alcohol swabs
Steps
- Wipe vial stoppers with alcohol swabs
- Draw 2 mL of BAC water into syringe
- Inject slowly into MT-1 vial — aim for glass wall, not powder
- Swirl gently until dissolved (2–5 minutes)
- Label with date and concentration
Dosing Math
2 mL into 10 mg gives clean math: 250 mcg = 5 units on insulin syringe.
Storage
- Refrigerate immediately (2–8°C / 36–46°F)
- Use within 28 days after reconstitution
- Don’t freeze reconstituted solution
- Light sensitive — store in original box or foil wrap
- Powder can be frozen (-20°C) long-term before reconstitution
Mechanism of Action
Melanotan-1 is a synthetic analog of α-MSH with high selectivity for MC1R receptors in melanocytes:
MC1R Activation — Binds melanocortin-1 receptors on melanocytes, triggering cAMP cascade and melanin synthesis. More selective than MT-2, which hits MC3R, MC4R, and MC5R ( Barnetson et al., 2006).
Eumelanin Production — Stimulates production of protective dark pigment (eumelanin) rather than red/yellow pheomelanin. This provides superior UV protection compared to natural tanning alone.
UV-Dependent Process — Unlike MT-2, requires UV stimulation for significant melanogenesis. Works synergistically with UV exposure to accelerate and enhance tanning response.
Photoprotection — Increases minimal erythema dose (MED) — the amount of UV needed to cause sunburn. Clinical studies show 2–3x improvement in UV tolerance ( Langendonk et al., 2015).
No Central Effects — Limited blood-brain barrier penetration means no appetite suppression, mood changes, or libido effects seen with MT-2.
Side Effects & Safety
Melanotan-1 has the cleanest safety profile in the melanotan family, backed by FDA approval.
What Clinical Studies Show
Phase III data ( Langendonk et al., 2015):
- Well-tolerated at 16mg implant doses
- No serious adverse events attributed to drug
- No effect on vital signs, lab values, or hormones
- Primary side effects: mild implant site reactions
Phase II injection studies ( Barnetson et al., 2006):
- Dose-dependent skin darkening as expected
- Mild injection site reactions
- No systemic toxicity at therapeutic doses
What the Community Reports
Most users report minimal side effects:
Common (but mild):
- Injection site redness lasting 30–60 minutes
- Gradual darkening of existing moles and freckles
- Mild fatigue on injection days (uncommon)
Rare:
- Mild nausea (much less than MT-2)
- Temporary appetite changes
- Skin flushing after injection
Key Safety Advantages Over MT-2
- No nausea or vomiting — MT-1 doesn’t significantly activate MC4R
- No libido effects — Limited central nervous system penetration
- No appetite suppression — Doesn’t affect feeding centers
- More predictable tanning — Requires UV, so tan develops gradually with sun exposure
Theoretical Concerns
- Mole darkening — May make it harder to detect skin cancer changes
- Excessive UV exposure — False confidence leading to overexposure
- Long-term melanocyte stimulation — Unknown effects of chronic use (though clinical data looks clean)
Stacking Melanotan-1
MT-1 is typically used alone, but some combinations are referenced in the community.
MT-1 + Controlled UV Exposure (Essential Combination)
This is really more protocol than stack — MT-1 requires UV to work effectively:
Gradual exposure protocol:
- Week 1: 10–15 minutes daily UV
- Week 2: 15–20 minutes daily
- Week 3+: 20–30 minutes daily or as tolerated
UV sources: Natural sunlight preferred, UVA/UVB tanning beds acceptable. Start conservatively regardless of natural skin type.
MT-1 + Antioxidants (Photoprotection Support)
Some users add antioxidants to support the increased UV exposure:
MT-1 + Other Tanning Peptides
Not recommended. Adding MT-2 or other melanocortins increases side effects without proportional benefits. MT-1’s selectivity is its advantage.
Frequently Asked Questions
What is the standard Melanotan-1 dose?
The most common community protocol is 250 mcg subcutaneously twice per week, typically Monday and Thursday mornings. This provides steady melanocortin stimulation without receptor saturation.
How does Melanotan-1 compare to Melanotan-2?
Melanotan-1 is more selective for MC1R receptors, causing fewer side effects — no nausea, libido changes, or appetite suppression. However, it requires UV exposure for tanning effects and works more slowly than MT-2.
Do I need UV exposure with Melanotan-1?
Yes — MT-1 primarily increases your response to UV radiation rather than independently darkening skin. Plan on 15–30 minutes of daily sun exposure during your cycle for best results.
How long should a Melanotan-1 cycle last?
Most protocols run 8 weeks on, 8 weeks off. Loading takes 2–4 weeks to build melanin, maintenance continues through week 8. Cycling prevents receptor desensitization and maintains effectiveness.
Is Melanotan-1 FDA-approved?
Yes, as afamelanotide for erythropoietic protoporphyria (EPP). It’s given as a 16mg subcutaneous implant every 2 months for this rare genetic condition. Community injection protocols extrapolate from this clinical data.
What are the side effects of Melanotan-1?
Much cleaner than MT-2. Primary side effects are mild injection site reactions and gradual darkening of existing moles/freckles. No appetite suppression, nausea, or libido effects characteristic of MT-2.
Can I use Melanotan-1 year-round?
Cycling (8 weeks on, 8 weeks off) is recommended to prevent receptor downregulation. Many users run it seasonally — spring loading for summer protection, or pre-vacation protocols.
How do I reconstitute Melanotan-1?
Add 2 mL bacteriostatic water to a 10 mg vial for 5,000 mcg/mL concentration. A 250 mcg dose equals 5 units on an insulin syringe. Swirl gently, refrigerate, use within 28 days.
Related Guides
- **Melanotan-1 Peptide Page** — Vendor pricing, detailed comparisons, and full peptide profile
- **Melanotan-2 Dosing Guide** — Alternative tanning peptide protocol
- **Melanotan 1 vs Melanotan 2** — Head-to-head comparison
- **Melanotan 2 Side Effects** — Why MT-1 has a better safety profile
- **PT-141 Dosing Guide** — Related melanocortin receptor peptide
- **Why Melanotan-1 Best Peptide** — Deep dive on MT-1 advantages
References
For educational and research purposes only. This is not medical advice. Consult healthcare providers before using any peptide protocol. Back to all articles
Originally published at https://thepeptidecatalog.com on February 17, 2026.
메타데이터
- post_id
- 6db46de79fe1
- slug
- melanotan-1-dosage-chart-fda-protocol-2026-the-peptide-catalog-6db46de79fe1
- url
- https://medium.com/@thepeptidecatalog/melanotan-1-dosage-chart-fda-protocol-2026-the-peptide-catalog-6db46de79fe1
- canonical_url
- https://medium.com/@thepeptidecatalog/melanotan-1-dosage-chart-fda-protocol-2026-the-peptide-catalog-6db46de79fe1
- author_url
- https://medium.com/@thepeptidecatalog
- status
- ok
- fetched_at
- 2026-07-17 03:11:29